Vivus reports bigger-than-expected 4th-qtr loss
Feb 25 (Reuters) - Vivus Inc's revenue for the first full quarter of selling its diet pill Qsymia fell short of analysts' estimates, and it posted a bigger-than-expected loss related to higher marketing expenses.
The company's fourth-quarter net loss rose to $56.7 million, or 56 cents per share, from $11.5 million, or 13 cents per share, a year earlier.
Net product revenue, reflecting sales of Qsymia, was $2 million in the fourth quarter, compared with $41,000 reported in the third quarter.
Vivus started generating revenue from the third quarter, when it began selling Qsymia.